Led · Equity · Sep 2025

Dianosic is a biotechnology company specializing in nasal drug-delivery solutions, notably a biorésorbable nasal implant. The implant is designed to treat chronic allergic rhinitis and rhinosinusitis. The company is also developing nose-to-brain delivery approaches aimed at neurological diseases such as Parkinson's and Alzheimer's. Dianosic announced a €7 million fundraising to accelerate its clinical and industrial development. The round is led by Aptar (Illinois), a global leader in drug-delivery systems, with participation from Noshaq (Liège), Capital Grand Est (Strasbourg) and Finovam Gestion (Lille). Co-founder and president Philippe Bastide said the financing validates the technology and will speed the company’s clinical and industrial progress. Dianosic develops therapeutic solutions for debilitating ENT conditions, including the ARIS family of treatments and the commercial CAVI-T device. The company intends to use new funding to finance a preclinical in vivo study and to launch a phase I clinical trial of its ARIS-R solution for chronic allergic rhinitis. In parallel it will continue developing ARIS-S for chronic sinusitis and explore other ENT applications. Dianosic also plans to use the funds to enhance the technical capability of its team. The company co-founded by Marc Augustin and CEO Philippe Bastide counts Prof. Christian Debry as scientific advisor. Its CAVI-T asymmetrical intranasal balloon is CE-marked, FDA-registered, and has been commercially available in Europe and the Middle East since 2021. Dianosic develops innovative medical devices for the management of ENT conditions. Its core product is CAVI-T, an asymmetrical intranasal balloon for hemostasis that stops spontaneous or postoperative nasal bleeding with low-pressure compression; CAVI-T was CE-marked in February 2020 and is patent-protected in France with planned coverage in Europe, the US, Japan and China. The company is also developing the Active Resorbable Intranasal Scaffold (ARIS) to deliver steroids for long-term (12-month) management of chronic sinusitis without requiring prior surgery. Dianosic intends to use its new funding to support the European launch of CAVI-T and to pursue ARIS development. The company was founded in July 2017 by Marc Augustin, Philippe Bastide and Pr Christian Debry and is incubated by SEMIA with support from the Grand Est regional ecosystem. Financially, Dianosic closed a first funding round of more than €1.5M in a mix of capital and non-dilutive funding.

Participated · Series A · Dec 2020

Founded in 2001 and based in Trenton, N.J., TerraCycle US builds and scales recycling solutions for materials not typically accepted in curbside programs, covering hundreds of waste streams such as snack wrappers, coffee pods, cosmetics, pet food bags, and car seats. The company reported growing U.S. revenue 75% over four years, from $24.7 million in 2020 to $43.1 million in 2024, and generated $19.3 million in gross profit in 2024 while remaining consistently profitable. TerraCycle US has completed three strategic acquisitions since 2018 to expand operational capabilities and strengthen its market position, and it has partnered with major brands and retailers including P&G, Nestle, and Walmart. The broader TerraCycle network has collected and recycled over 8 billion items, raised $20 million for schools and nonprofits, and received numerous industry awards. The company intends to use proceeds from the Regulation A raise to fund further strategic acquisitions and disciplined growth to drive recurring revenue and durable market leadership.

Led · Equity · May 2018

Propeller Health provides a platform and connected devices that enable medical technology and pharmaceutical companies to conceptualize, develop and commercialize digital medicines, with an initial focus on chronic respiratory disease. The company offers distribution at scale through the Propeller Provider Network and partnerships with payers, pharmacies and PBMs such as Express Scripts. Led by co‑founder and CEO David Van Sickle and based in Madison, Wis., Propeller’s platform is backed by eight FDA 510(k) clearances and CE marking. The company is working with industry experts and regulators to advance clinical research, real‑world evidence and the design and validation of novel endpoints. Propeller intends to invest in its pipeline of digital therapeutics and additional connected devices and to begin developing digital medicines for new therapeutic areas using proceeds from its recent raise. It has also announced a strategic partnership with Aptar Pharma to co‑develop and co‑market digital medicines across therapeutic areas. Propeller Health builds a sensor and software platform that monitors breaths, uploads patient data to clinicians, and helps head off asthma attacks and other respiratory events. The company launched in 2010 with a sensor and cloud platform aimed at improving disease management. Propeller has developed more than 45 programs with healthcare providers, including Dignity Health and managed-care systems covered by Molina Healthcare. Leadership says the company plans to add more devices and medications to its platform and to expand globally. It targets the more than 37 million people in the U.S. with asthma and other respiratory diseases. Financially, Propeller has raised $45 million to date, including the newly closed $21.5 million Series C. Propeller Health develops a digital therapeutic combining inhaler sensors, mobile apps, analytics and personalized feedback to help patients and physicians understand and control COPD, asthma and other respiratory diseases. Led by CEO and co-founder David Van Sickle and recently added COO Chris Hogg, the system encourages adherence to maintenance therapy, remotely monitors rescue-medication use, predicts exacerbations and facilitates early intervention by care teams. The company recently doubled its number of commercial programs, added its first contract with an accountable care organization, received FDA clearance for a new inhaler sensor, and is concluding a 500-person randomized controlled trial at Dignity Health. Propeller intends to use the Series B funds to accelerate product development, strategic alliances, client services, and sales and marketing. The company is actively recruiting engineering, product, user-experience design, data and other personnel to support growth. Launched in 2010 and based in Wisconsin, Asthmapolis makes snap-on, Bluetooth-enabled sensors for inhalers plus analytics and mobile apps for iOS and Android to log medication use and context. The platform captures time, location and usage data to help users visualize triggers and trends and to deliver personalized feedback. Early studies reported that access to the realtime data reduced the number of people with uncontrolled asthma or irregular inhaler use by 50%. Asthmapolis received FDA approval in July to market its asthma-tracking device and software to consumers. The company monetizes by selling its hardware and software solution to payers and health plan providers, arguing insurance providers and health plans can save between $4,000 and $6,000 in annual healthcare costs per patient. It has formed partnerships with payers and providers including Amerigroup Florida/WellPoint, Wyckoff Heights Medical Center and Dignity Health, and plans to expand relationships with providers, payers, retail pharmacy and the public sector.